105 related articles for article (PubMed ID: 27466518)
41. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
42. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
43. Palmar-plantar erythrodysesthesia.
Wilkes GM; Doyle D
Clin J Oncol Nurs; 2005 Feb; 9(1):103-6. PubMed ID: 15751504
[No Abstract] [Full Text] [Related]
44. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Weycker D; Edelsberg J; Kartashov A; Barron R; Lyman G
Chemotherapy; 2012; 58(1):8-18. PubMed ID: 22343254
[TBL] [Abstract][Full Text] [Related]
45. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.
Formenti SC; Volm M; Skinner KA; Spicer D; Cohen D; Perez E; Bettini AC; Groshen S; Gee C; Florentine B; Press M; Danenberg P; Muggia F
J Clin Oncol; 2003 Mar; 21(5):864-70. PubMed ID: 12610186
[TBL] [Abstract][Full Text] [Related]
46. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Cassier PA; Chabaud S; Trillet-Lenoir V; Peaud PY; Tigaud JD; Cure H; Orfeuvre H; Salles B; Martin C; Jacquin JP; Agostini C; Guastalla JP; Pérol D; Bachelot T
Breast Cancer Res Treat; 2008 May; 109(2):343-50. PubMed ID: 17611792
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
48. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
49. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer.
Syrigos KN; Michalaki B; Alevyzaki F; Machairas A; Mandrekas D; Kindilidis K; Karatzas G
Anticancer Res; 2002; 22(6B):3583-8. PubMed ID: 12552960
[TBL] [Abstract][Full Text] [Related]
50. Docetaxel in combination with fluorouracil: study design and preliminary results.
Rowinsky E; Smith L; Rodriguez G; White L; Drengler R; Von Hoff D; Peacock N; Aylesworth C; Burris H; Ravdin P; Bellet R
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):33-5. PubMed ID: 9213326
[TBL] [Abstract][Full Text] [Related]
51. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide.
Kasapović J; Pejić S; Stojiljković V; Todorović A; Radošević-Jelić L; Saičić ZS; Pajović SB
Clin Biochem; 2010 Nov; 43(16-17):1287-93. PubMed ID: 20713039
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
53. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
[TBL] [Abstract][Full Text] [Related]
54. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
Qi M; Li JF; Xie YT; Lu AP; Lin BY; Ouyang T
Breast Cancer Res Treat; 2010 Aug; 123(1):197-202. PubMed ID: 20582466
[TBL] [Abstract][Full Text] [Related]
55. Paclitaxel-induced dorsal hand-foot syndrome.
Quan EY; Engel C; Rush PS; Eikenberg JD
Dermatol Online J; 2023 Jun; 29(3):. PubMed ID: 37591274
[TBL] [Abstract][Full Text] [Related]
56. Effects of chemotherapeutic agents on male germ cells and possible ameliorating impact of antioxidants.
Ghafouri-Fard S; Shoorei H; Abak A; Seify M; Mohaqiq M; Keshmir F; Taheri M; Ayatollahi SA
Biomed Pharmacother; 2021 Oct; 142():112040. PubMed ID: 34416630
[TBL] [Abstract][Full Text] [Related]
57. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Spigel DR; Hainsworth JD; Burris HA; Molthrop DC; Peacock N; Kommor M; Vazquez ER; Greco FA; Yardley DA
Clin Adv Hematol Oncol; 2011 Apr; 9(4):280-6. PubMed ID: 21558987
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
59. Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy.
Hwang YY; Trendell-Smith NJ; Yeung CK; Kwong YL
Acta Haematol; 2012; 128(3):151-3. PubMed ID: 22890199
[No Abstract] [Full Text] [Related]
60. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
